These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9331609)

  • 41. Erysipelas. Changing faces.
    Ronnen M; Suster S; Schewach-Millet M; Modan M
    Int J Dermatol; 1985 Apr; 24(3):169-72. PubMed ID: 3997339
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recurrent erysipelas despite antibiotic prophylaxis: an analysis from case studies.
    Koster JB; Kullberg BJ; van der Meer JW
    Neth J Med; 2007 Mar; 65(3):89-94. PubMed ID: 17387234
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Immune preparations in the overall therapy and prevention of erysipelatous inflammation].
    Khlestkov AA; Raskovalov MG; Ebert LIa
    Voen Med Zh; 1976 Jan; (1):48-9. PubMed ID: 1258419
    [No Abstract]   [Full Text] [Related]  

  • 44. [Characteristics of the clinical course of erysipelas in the middle-aged and elderly].
    Postovit VA; Mel'k MV
    Sov Med; 1981; (3):100-4. PubMed ID: 7244822
    [No Abstract]   [Full Text] [Related]  

  • 45. Association of erysipelas with acute renal failure.
    de Godoy JM; Irikura MK; de Moura Álvares R; Quintino E
    Int Urol Nephrol; 2011 Sep; 43(3):917-8. PubMed ID: 20508989
    [No Abstract]   [Full Text] [Related]  

  • 46. [Chronic recurring erysipelas].
    Naseman T
    Dtsch Med Wochenschr; 1973 Apr; 98(16):846. PubMed ID: 4266620
    [No Abstract]   [Full Text] [Related]  

  • 47. [Erysipelas of the leg in hospital environment in Lome (Togo)].
    Pitche P; Tchangaï-Walla K
    Bull Soc Pathol Exot; 1997; 90(3):189-91. PubMed ID: 9410258
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recurrent erysipelas: risk factors.
    Pavlotsky F; Amrani S; Trau H
    J Dtsch Dermatol Ges; 2004 Feb; 2(2):89-95. PubMed ID: 16279242
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Compression is important in erysipelas treatment].
    Villefrance M; Høgh A; Kristensen LH
    Ugeskr Laeger; 2017 Oct; 179(41):. PubMed ID: 28992840
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Erysipelas].
    van der Waal RI
    Ned Tijdschr Tandheelkd; 2011 Jun; 118(6):308. PubMed ID: 21766527
    [No Abstract]   [Full Text] [Related]  

  • 51. Monitoring of drowning and near-drowning in the Czech Republic in the years 2001-2002.
    Capková M; Velemínský M; Benesová V; Grivna M
    Int J Inj Contr Saf Promot; 2006 Mar; 13(1):43-5. PubMed ID: 16537223
    [No Abstract]   [Full Text] [Related]  

  • 52. Erysipelas of the upper extremity following locoregional therapy for breast cancer.
    El Saghir NS; Otrock ZK; Bizri AR; Uwaydah MM; Oghlakian GO
    Breast; 2005 Oct; 14(5):347-51. PubMed ID: 15990307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Erysipelas--course of disease, recurrence, complications; a 10 years retrospective study].
    Wojas-Pelc A; Alekseenko A; Jaworek AK
    Przegl Epidemiol; 2007; 61(3):457-64. PubMed ID: 18069381
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relapsing erysipelas of the buttock due to Streptococcus agalactiae in an immunocompetent woman.
    Bachmeyer C; Begon E; Martres P; Blum L
    Clin Exp Dermatol; 2009 Mar; 34(2):267-8. PubMed ID: 19187312
    [No Abstract]   [Full Text] [Related]  

  • 55. Recurrent erysipelas: predisposing factors and costs of prophylaxis.
    Jorup-Rönström C; Britton S
    Infection; 1987; 15(2):105-6. PubMed ID: 3110071
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk factors associated with local complications of erysipelas: a retrospective study of 152 cases.
    Titou H; Ebongo C; Bouati E; Boui M
    Pan Afr Med J; 2017; 26():66. PubMed ID: 28451043
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Head phlegmon as a complication of eyelids erysipelas--two cases in one family].
    Szołdra-Seiler A; Horbacz-Jary G
    Otolaryngol Pol; 2008; 62(6):779-81. PubMed ID: 19205531
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Recurrent erysipelas and cellulitis: management].
    Zürcher S; Trellu LT
    Rev Med Suisse; 2015 Apr; 11(468):759-62. PubMed ID: 26021136
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk factors for abscess formation in patients with superficial cellulitis (erysipelas) of the leg.
    Picard D; Klein A; Grigioni S; Joly P
    Br J Dermatol; 2013 Apr; 168(4):859-63. PubMed ID: 23210619
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Erysipelas after breast cancer treatment (26 cases).
    Masmoudi A; Maaloul I; Turki H; Elloumi Y; Marrekchi S; Bouassida S; Ben Jemaa M; Zahaf A
    Dermatol Online J; 2005 Dec; 11(3):12. PubMed ID: 16409908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.